Telix and Atlab Working to Develop Antibody for Radioimmunotherapy in Advanced Cancers

Telix and Atlab Working to Develop Antibody for Radioimmunotherapy in Advanced Cancers
Telix Pharmaceuticals and Atlab Pharma are working together to develop and possibly market huJ591, a monoclonal antibody to be used in radioimmunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the agreement, Telix will financially support the production and clinical development of huJ591, an anti-PSMA antibody linked to radioactive lutetium-177 (Lu-177) and astatine-211

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *